Grupo Oncoclínicas, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
CORA, Advanced Center for Diagnosis of Breast Diseases, Federal University of Goias, Goiânia, Brazil.
JCO Glob Oncol. 2021 Apr;7:474-485. doi: 10.1200/GO.20.00566.
The objective of this review is to address the barriers limiting access to treatment of advanced metastatic breast cancer (mBC) in Brazil, specifically for patients in the public health care system, arguably those with the least access to innovation.
A selected panel of Brazilian experts in BC were provided with a series of relevant questions to address in a multiday conference. During the conference, responses were discussed and edited by the entire group through numerous drafts and rounds of discussion until a consensus was achieved.
The authors propose specific and realistic recommendations for implementing access to new drugs in cancer care in Brazil. Moreover, in creating these recommendations and framework, the authors strive to address the most important barriers and impediments for technology incorporation. A feasible and specific multidisciplinary process is proposed, which is based on the collective participation of all involved stakeholders.
Given the current benefits and likely future developments, there is a great need to expand treatments for mBC not only in Brazil but also in most other countries in the world where access issues remain an unresolved demand. Adapting the current framework is essential for accomplishing this goal. The recommendations in this review can serve as a framework for adoption of new technologies in countries with limited resources.
本综述旨在探讨限制巴西晚期转移性乳腺癌(mBC)治疗的障碍,特别是对于公共医疗保健系统中的患者,这些患者可能是最难以获得创新治疗的人群。
一组巴西乳腺癌专家针对一系列相关问题进行了讨论。在会议期间,通过多轮草稿和讨论,整个专家组对答复进行了讨论和编辑,直到达成共识。
作者提出了在巴西癌症治疗中实施新药准入的具体而现实的建议。此外,在提出这些建议和框架时,作者努力解决技术引入的最重要障碍和障碍。提出了一种可行且具体的多学科流程,该流程基于所有相关利益相关者的集体参与。
鉴于当前的获益和未来可能的发展,不仅在巴西,而且在世界上大多数其他国家,都非常需要扩大对 mBC 的治疗,因为这些国家的治疗准入问题仍然是一个未解决的需求。适应当前框架对于实现这一目标至关重要。本综述中的建议可以作为资源有限的国家采用新技术的框架。